Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

Data ReadoutpositiveNETosis TestPositive

AI Analysis

Summary

VolitionRx announced results demonstrating the utility of its rapid, point-of-care finger-prick NETosis test in sepsis patients, eliminating the need for centralized laboratory processing. The test addresses a $3.8 billion global addressable market for NETosis testing.

Outcome Details

Demonstrates utility of rapid, point-of-care finger-prick test in sepsis patients; removes centralized lab dependency

Importance:6/10

Sentiment:

0.70

diagnosticssepsispoint-of-care testingepigeneticsNETosis

Related Companies

$VNRX

Read the original article

Published by PR Newswire Biotech on August 12, 2026 12:17 PM

Read Original